Ulisse Biomed S.p.A.

UBM

IT0005451213

Biotechnology & Medical Research

Market Closed - Borsa Italiana Other stock markets 09:14:59 03/06/2024 pm IST			5-day change	1st Jan Change
1.155 ^EUR	+0.43%		-0.86%	-30.21%

27/05	Ulisse Biomed, agreement with Elettrobiochimica for IVDR kit development	AN
20/05	Ulisse Biomed S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Ulisse Biomed S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023

May 20, 2024 at 04:37 am IST

Ulisse Biomed S.p.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 0.066208 million. Revenue was EUR 0.263153 million.

Net loss was EUR 4.8 million.

Latest news about Ulisse Biomed S.p.A.

Ulisse Biomed, agreement with Elettrobiochimica for IVDR kit development	27/05	AN
Ulisse Biomed S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	20/05	CI
Ulisse Biomed, Sbaizero resigns as independent director	09/05	AN
Ulysses Biomed reduces loss in 2023; NFP is positive	03/05	AN
Mib positive; MPS updates annual high	02/05	AN
Futures bullish; Mib restarts at 33,700 points	02/05	AN
Mib in the red; Stellantis gives up double digits	30/04	AN
Ulisse Biomed, subsidiary sign distribution agreement with Mediline	18/03	AN
Europe's only Mib in green; Webuild bullish	05/03	AN
Indices down except in Mib; Saipem on top	05/03	AN
Ulisse Biomed, subsidiary sign partnership agreement with Generon	04/03	AN
Ulysses Biomed subsidiary concludes project worth more than EUR1 million	20/02	AN
Indexes in the red; Eurozone sentiment improves	13/02	AN
Banks weigh on Mib in the red	13/02	AN
Ulisse Biomed has a new board of directors, Lo Priore chairman and Basile CEO	12/02	AN
Hyris Fulfils Its Integration into Ulisse Biomed to Give Birth to A New International Group	15/01	CI
Futures bearish; new US data expected.	03/01	AN
Good banks and oil, Mib opens the year higher	02/01	AN
Ulysses Biomed, board of directors and board of auditors resign	29/12	AN
Futures bullish; wait for Fed cuts in 2024	29/12	AN
Listings in the red; banks weigh on Mib.	28/12	AN
Ulysses Biomed, subsidiary sign agreement for agricultural test development	28/12	AN
Ulisse Biomed approves reverse take-over and aucap; Lo Priore new chair	21/12	AN
Further rises expected on European stock markets.	06/12	AN
Mib at highest since 2008; Pirelli shows muscles	05/12	AN

Ulisse Biomed Spa is an Italy-based company engaged in the healthcare biotech sector. The Company focuses on creating new and transformative diagntostic platforms and products. It creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Ratings for Ulisse Biomed S.p.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ULISSE BIOMED S.P.A.	-30.21%	27.19M
MODERNA, INC.	+45.86%	54.63B
IQVIA HOLDINGS INC.	-6.71%	39.92B
LONZA GROUP AG	+37.07%	38.82B
ICON PUBLIC LIMITED COMPANY	+13.27%	26.86B
CELLTRION, INC.	-11.17%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-21.63%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.48%	12.21B
BIO-TECHNE CORPORATION	+0.31%	12.16B
MEDPACE HOLDINGS, INC.	+25.74%	11.94B

Other Biotechnology & Medical Research